MX9304611A - Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. - Google Patents

Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Info

Publication number
MX9304611A
MX9304611A MX9304611A MX9304611A MX9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A
Authority
MX
Mexico
Prior art keywords
crystalline hydrate
triazolyltiomethyl
clohydrate
cephalosporine
preparation
Prior art date
Application number
MX9304611A
Other languages
English (en)
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX9304611A publication Critical patent/MX9304611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el clorhidrato del ácido 7-beta-[(Z)-(2-amino-4-tiazolil)-2-hidroxiiminoace tamino]-3-cefem-4-carboxílico y su hidrato cristalino, los cuales tienen una potente actividad antibiótica y son de baja toxicidad y farmacéuticamente estables, con lo cual son útiles como ingredientes activo de formulaciones antibióticas clínicamente útiles, y la producción de los mismos.
MX9304611A 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. MX9304611A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
MX9304611A true MX9304611A (es) 1994-02-28

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304611A MX9304611A (es) 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Country Status (23)

Country Link
US (1) US5407929A (es)
EP (1) EP0581552B1 (es)
KR (1) KR100245938B1 (es)
CN (1) CN1037683C (es)
AT (1) ATE165360T1 (es)
AU (1) AU657866B2 (es)
BR (1) BR9303235A (es)
CA (1) CA2101502A1 (es)
DE (1) DE69318077T2 (es)
ES (1) ES2115725T3 (es)
FI (1) FI933391A7 (es)
GR (1) GR3026699T3 (es)
HU (1) HU219637B (es)
IL (1) IL106516A (es)
MX (1) MX9304611A (es)
NO (1) NO303734B1 (es)
NZ (1) NZ248285A (es)
PH (1) PH30109A (es)
PL (2) PL172835B1 (es)
RU (1) RU2118959C1 (es)
TW (1) TW307769B (es)
UA (1) UA37181C2 (es)
ZA (1) ZA935529B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
WO2004072040A1 (en) 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
MXPA05010083A (es) 2003-03-27 2005-11-23 Basilea Pharmaceutica Ag Cefalosporina en forma cristalina.
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) * 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
KR100245938B1 (ko) 2000-04-01
FI933391L (fi) 1994-02-01
ZA935529B (en) 1994-02-24
HUT68602A (en) 1995-06-28
PL172835B1 (pl) 1997-12-31
EP0581552B1 (en) 1998-04-22
EP0581552A3 (en) 1994-06-01
TW307769B (es) 1997-06-11
PL299870A1 (en) 1994-02-07
NO303734B1 (no) 1998-08-24
ATE165360T1 (de) 1998-05-15
RU2118959C1 (ru) 1998-09-20
HU9302194D0 (en) 1993-10-28
EP0581552A2 (en) 1994-02-02
US5407929A (en) 1995-04-18
DE69318077T2 (de) 1998-10-29
NO932745D0 (no) 1993-07-30
FI933391A0 (fi) 1993-07-29
NZ248285A (en) 1994-07-26
AU657866B2 (en) 1995-03-23
AU4422793A (en) 1994-02-03
BR9303235A (pt) 1994-03-01
IL106516A0 (en) 1993-11-15
DE69318077D1 (de) 1998-05-28
IL106516A (en) 1998-06-15
PL172830B1 (pl) 1997-12-31
FI933391A7 (fi) 1994-02-01
CA2101502A1 (en) 1994-02-01
KR940005636A (ko) 1994-03-22
GR3026699T3 (en) 1998-07-31
UA37181C2 (uk) 2001-05-15
ES2115725T3 (es) 1998-07-01
CN1037683C (zh) 1998-03-11
PH30109A (en) 1996-12-27
CN1089948A (zh) 1994-07-27
NO932745L (no) 1994-02-01
HU219637B (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
BR0009176A (pt) Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
EP0937459A3 (en) Pharmaceutical compositions for the treatment of ischemic brain damage
BR9303235A (pt) Compostos e processo para sua preparacao,formulacao farmaceutica,metodo para o combate de bacterias e metodo para o tratamento de infecoes bacterianas
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
BR0313162A (pt) Composto, processo para preparar o mesmo, e, composição farmacêutica
ES2054949T3 (es) Precursores de dopamina.
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
IT1271456B (it) Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
JP2000159790A5 (es)
ES2057225T3 (es) Una composicion para la preparacion de una vitamina d3 activa en forma de dosificacion y su procedimiento de preparacion.
DE69915487D1 (de) Erythromycin-derivate mit antibiotischer wirkung
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ES8605532A1 (es) Un procedimiento para preparar derivados de aminoglicosido
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
IE37250B1 (en) Diazepine derivatives and processes for their production
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
AR026451A1 (es) Compuestos heterociclicos sililados
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas